D. Teitelbaum

发表

A simple fluorescent method to determine complement-mediated liposome immune lysis.

M. Sela, C. Gitler, M. Smolarsky, 1977, Journal of immunological methods.

Binding of random copolymers of three amino acids to class II MHC molecules.

J. Strominger, M. Sela, R. Arnon, 1999, International immunology.

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1.

A. Meshorer, M. Sela, R. Arnon, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells.

M. Sela, R. Arnon, M. Fridkis-Hareli, 1995, Cellular immunology.

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

M. Sela, R. Arnon, C. Brautbar, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

M. Sela, R. Arnon, R. Milo, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1.

M. Sela, R. Arnon, R. Aharoni, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids.

M. Sela, R. Arnon, A. Herz, 1976, Immunochemistry.

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.

M. Sela, R. Arnon, R. Aharoni, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Protection against Experimental Allergic Encephalomyelitis

A. Meshorer, M. Sela, R. Arnon, 1972, Nature.

Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.

M. Sela, R. Arnon, D. Teitelbaum, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1.

M. Sela, R. Arnon, R. Aharoni, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Basic encephalitogenic protein: A simplified purification on sulphoethyl‐sephadex

M. Sela, R. Arnon, D. Teitelbaum, 1970, FEBS letters.

Copolymer 1 inhibits manifestations of graft rejection.

M. Sela, R. Arnon, R. Aharoni, 2001, Transplantation.

Multiple sclerosis: Trial of a synthetic polypeptide

M. Sela, R. Arnon, M. Bornstein, 1982, Annals of neurology.

Copolymer 1: from basic research to clinical application

M. Sela, R. Arnon, D. Teitelbaum, 1997, Cellular and Molecular Life Sciences CMLS.

2-31-01 Copolymer 1 inhibits the response to myelin basic protein p84-102 by T cell receptor antagonism in addition to MHC blocking

M. Sela, R. Arnon, R. Aharoni, 1997, Journal of the Neurological Sciences.

Cop 1 as a candidate drug for multiple sclerosis.

M. Sela, R. Arnon, D. Teitelbaum, 1997, Journal of neural transmission. Supplementum.

Sphingomyelin specific antibodies elicited by synthetic conjugates.

M. Sela, R. Arnon, D. Teitelbaum, 1973, Immunochemistry.

Clinical Trials of Copolymer I in Multiple Sclerosis

M. Sela, R. Arnon, M. Bornstein, 1984, Annals of the New York Academy of Sciences.

New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

M. Sela, R. Arnon, D. Teitelbaum, 1996, Journal of neurology.

Clinical trials of a synthetic polypeptide (Copolymer I) for the treatment of multiple sclerosis

M. Sela, R. Arnon, M. Bornstein, 1984 .

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.

M. Sela, R. Arnon, R. Aharoni, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer.

A. Meshorer, M. Sela, R. Arnon, 1974, Clinical immunology and immunopathology.

Strain differences in susceptibility to experimental allergic encephalomyelitis and the immune response to the encephalitogenic determinant in inbred guinea pigs.

M. Sela, R. Arnon, D. Teitelbaum, 1977, Cellular immunology.

Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells.

M. Sela, R. Arnon, I. Pecht, 1997, International immunology.

A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis

M. Sela, R. Arnon, S. Appel, 1991, Neurology.

Inverse relationship between net electric charge on the antigen and that on the sensitized cell in cellular immune response: demonstration with basic encephalitogen of the brain

M. Sela, R. Arnon, H. Rauch, 1975, The Journal of experimental medicine.

Treatment of multiple sclerosis with a synthetic polypeptide: preliminary results.

M. Sela, A. Miller, R. Arnon, 1980, Transactions of the American Neurological Association.

Copolymer 1 from the laboratory to FDA.

M. Sela, R. Arnon, D. Teitelbaum, 1997, Israel journal of medical sciences.